I am a physician and specialty registrar in clinical pharmacology studying how pharmacogenetic test results change prescribing and patient outcomes. I combine Danish national registry data with prospective clinical trials to measure whether genotype-guided dosing reduces adverse drug reactions and treatment failures.
My current work focuses on CYP2C19-guided antiplatelet therapy, SLCO1B1 genotyping for statin intolerance, and therapeutic drug monitoring of targeted cancer therapies.
Experience
Specialty registrar in clinical pharmacology | 2023 to 2027
- Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital (current)
- Department of Clinical Biochemistry and Genomic Medicine, Rigshospitalet (2025 to 2026)
- Department of Endocrinology, Herlev Hospital (2024 to 2025)
- Cardiovascular Clinical Development, Novo Nordisk (2023 to 2024)
Resident | Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital | 2021 to 2023
Postdoctoral researcher | CLL-LAB, Department of Hematology, Rigshospitalet | 2020 to 2021
Education
PhD in Medical Science | University of Copenhagen | 2016 to 2021
- Thesis: Real-world evidence on the risk, type and treatment of infectious complications in chronic lymphocytic leukaemia
Medical Doctor (MD) | University of Copenhagen | 2008 to 2015
Positions
- Chair, Danish Society for Personalized Medicine (2025 to present)
- Appointed national expert, Danish National Strategy for Personalized Medicine (2026 to present)
- Auditor, Danish Society of Clinical Pharmacology (2026 to present)
- Working group member, CPIC guideline for NAT2 (published 2025)
- Review editor, Frontiers in Epidemiology (2023 to present)
- Member, Clinical Pharmacogenetics Implementation Consortium (CPIC) (2022 to present)
- Member, Pharmacogenomics Global Research Network (2022 to present)